Skip to main content
SpringerLink
Log in

The Thrombocytopenic Purpuras

Recognition and Management

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP), are distinct entities. ITP is a relatively common autoimmune disorder typically manifesting with isolated thrombocytopenia. The acute form, more common in children, is a self-limiting, often post-viral disease. Therapy, if indicated, usually consists of a brief course of steroids or intravenous IgG. Chronic ITP, more common in adults, rarely remits spontaneously. Most patients respond initially to steroids, j but generally the disease relapses when steroids are tapered. Splenectomy offers a 70% chance of cure. A variety of treatment options exist for patients not responding to splenectomy. The treating physician must choose the most effective and least toxic treatment for the individual patient.

TTP is a rare, often life-threatening, multisystem disease of unknown aetiology. Its hallmark is widespread occlusion of the microcirculation by platelet aggregates. The clinical symptoms usually respond dramatically to plasma exchange therapy. Steroids, antiplatelet agents and vincristine may also be useful. Splenectomy should be considered in patients with multiple relapses. More specific therapy awaits a fuller understanding of the pathogenesis of this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the cooperative Latin America group on hemostasis and thrombosis. Blood 1984; 64: 1179–83

    CAS  PubMed  Google Scholar 

  2. Ben-Yehuda D, Gillis S, Eldor A, et al. Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Acta Haematol 1994; 91: 1–6

    CAS  PubMed  Google Scholar 

  3. Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral Prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994; 344: 703–7

    CAS  PubMed  Google Scholar 

  4. George J, El-Harake M, Raskob G. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 1994; 331: 1207–11

    CAS  PubMed  Google Scholar 

  5. Eden O, Lilleyman J. Guidelines for management of idiopathic thrombocytopenic purpura. Arch Dis Child 1992; 67: 1056–8

    CAS  PubMed  Google Scholar 

  6. Menell JS, Bussel JB. Antenatal management of the thrombocytopenias. Clin Perinatal 1994; 21: 591–614

    CAS  Google Scholar 

  7. Ozsoylu S, Karabent A, Irken G, et al. Antiplatelet antibodies in childhood idiopathic thrombocytopenic purpura. Am J Hematol 1991; 36: 82–5

    CAS  PubMed  Google Scholar 

  8. Taub JW, Warrier I, Holtkamp C, et al. Characterization of autoantibodies against the platelet glycoprotein antigens IIb/IIIa in childhood idiopathic thrombocytopenic purpura. Am J Hematol 1995; 48: 104–7

    CAS  PubMed  Google Scholar 

  9. Lilleyman J. Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Arch Dis Child 1994; 71: 251–3

    CAS  PubMed  Google Scholar 

  10. Blanchette V, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993; 123: 989–95

    CAS  PubMed  Google Scholar 

  11. Albayrak D, Islek I, Kalayci AG, et al. Acute immune thrombocytopenic purpura: a comparative study of very high oral doses of methylprednisolone and intravenously administered immune globulin. J Pediatr 1994; 125: 1004–7

    CAS  PubMed  Google Scholar 

  12. Dubansky AS, Oski FA. Controversies in the management of acute idiopathic thrombocytopenic purpura: a survey of specialists. Pediatrics 1986; 77: 49–52

    CAS  PubMed  Google Scholar 

  13. Lilleyman JS. Treatment of childhood immune thrombocytopenic purpura [letter]. Lancet 1994; 344: 1155

    CAS  PubMed  Google Scholar 

  14. Bussel JB, Graziano JN, Kimberly RP, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood 1991; 77: 1884–93

    CAS  PubMed  Google Scholar 

  15. Borgna-Pignatti C, Battisti L, Zecca M, et al. Treatment of chronic childhood immune thrombocytopenic purpura with intramuscular anti-D immunoglobulins. Br J Haematol 1994; 88: 618–20

    CAS  PubMed  Google Scholar 

  16. Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. Br J Surg 1991; 78: 1031–8

    CAS  PubMed  Google Scholar 

  17. Tamary H, Kaplinsky C, Levy I, et al. Chronic childhood idiopathic thrombocytopenic purpura: long-term follow up. Acta Paediatr 1994; 83: 931–4

    CAS  PubMed  Google Scholar 

  18. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436–42

    CAS  PubMed  Google Scholar 

  19. Doan CA, Bouroncle BA, Wiseman BK. Idiopathic and secondary thrombocytopenic purpura: a clinical study and evaluation of 381 cases over a period of 28 years. Ann Intern Med 1960; 53: 861–76

    Google Scholar 

  20. Karpatkin S. Immunologic thrombocytopenic purpura in HIV-seropositive homosexuals, narcotic addicts and hemophiliacs. Semin Hematol 1988; 25: 219–29

    CAS  PubMed  Google Scholar 

  21. Bizzaro N. EDTA-dependent pseudothrombocytopenia: a clinical and epidemiological study of 112 cases, with 10-year follow-up. Am J Hematol 1995; 50: 103–9

    CAS  PubMed  Google Scholar 

  22. Fujisawa K, Tani P, Piro L, et al. The effect of therapy on platelet-associated autoantibody in chronic immune thrombocytopenic purpura. Blood 1993; 81: 2872–7

    CAS  PubMed  Google Scholar 

  23. Ruyihe B, Reid DM, Jones CE, et al. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994; 83: 1024–32

    Google Scholar 

  24. Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood 1993; 81: 1246–50

    CAS  PubMed  Google Scholar 

  25. Bellud S, Charpak Y, Chastang C, et al. Low doses vs. conventional doses of corticoids in immune thrombocytopenic purpura (ITP): results of a randomized clinical trial in 160 children, 223 adults. Blood 1988; 71: 1165–9

    Google Scholar 

  26. Chirletti P, Cardi M, Barillari P, et al. Surgical treatment of immune thrombocytopenic purpura. World J Surg 1992; 16: 1001–5

    CAS  PubMed  Google Scholar 

  27. Gigot JF, Healy ML, Ferrant A, et al. Laparoscopic splenectomy for idiopathic thrombocytopenic purpura. Br J Surg 1994; 81: 1171–2

    CAS  PubMed  Google Scholar 

  28. Caulier MT, Darloy F, Rose C, et al. Splenic irradiation for chronic autoimmune thrombocytopenic purpura in patients with contra-indications to splenectomy. Br J Haematol 1995; 91: 208–11

    CAS  PubMed  Google Scholar 

  29. Reid MM. Splenectomy, sepsis, immunisation and guidelines. Lancet 1994; 344: 970–1

    CAS  PubMed  Google Scholar 

  30. McMullin M, Johnston G. Long term management of patients after splenectomy. BMJ 1993; 307: 1372–3

    CAS  PubMed  Google Scholar 

  31. Makris M, Greaves M, Winfield DA, et al. Lifelong penicillin unproved in trials. BMJ 1994; 308: 131–2

    CAS  PubMed  Google Scholar 

  32. Schattner E, Bussel J. Mortality in immune thrombocytopenic purpura: report of seven cases and consideration of prognostic indicators. Am J Hematol 1994; 46: 120–6

    CAS  PubMed  Google Scholar 

  33. Cortelazzo S, Finazzi G, Buelli M, et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991; 77: 31–3

    CAS  PubMed  Google Scholar 

  34. Linares M, Cervero A, Colomina P, et al. Chronic idiopathic thrombocytopenic purpura in the elderly. Acta Haematol 1995; 93: 80–2

    CAS  PubMed  Google Scholar 

  35. Quiquandon I, Fenaux P, Caulier MT, et al. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report of 53 cases. Br J Haematol 1990; 74: 223–8

    CAS  PubMed  Google Scholar 

  36. Srichaikul T, Boonpucknavig S, Archararit N, et al. Chronic immunologic thrombocytopenic purpura. Results of cyclophosphamide therapy before splenectomy. Arch Intern Med 1980; 140: 636–8

    Google Scholar 

  37. Ahn YS, Harrington WJ, Simon SR, et al. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med 1983; 308: 1396–9

    CAS  PubMed  Google Scholar 

  38. McVerry BA, Auger M, Bellingham AJ. The use of Danazol in the management of chronic immune thrombocytopenic purpura. Br J Haematol 1985; 61: 145–8

    CAS  PubMed  Google Scholar 

  39. Facon T, Caulier MT, Wattel E, et al. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol 1994; 86: 678–80

    CAS  Google Scholar 

  40. Godeau B, Lesage S, Divine M, et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993; 82: 1415–21

    CAS  PubMed  Google Scholar 

  41. Schiavotto C, Ruggeri M, Rodeghiero F. Failure of repeated courses of high-dose intravenous immunoglobulin to induce stable remission in patients with chronic idiopathic thrombocytopenic purpura. Ann Hematol 1995; 70: 89–90

    CAS  PubMed  Google Scholar 

  42. Jubelirer SJ. Pilot study of ascorbic acid for the treatment of refractory idiopathic thrombocytopenic purpura. Am J Hematol 1993; 43: 44–6

    CAS  PubMed  Google Scholar 

  43. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 1994; 330: 1560–4

    CAS  PubMed  Google Scholar 

  44. Godeau B, Zini J-M, Schaeffer A, et al. High-dose methylprednisone is an alternative treatment for adults with autoimmune thrombocytopenic purpura refractory to intravenous immunoglobulins and oral corticosteroids. Am J Hematol 1995; 48: 282–4

    CAS  PubMed  Google Scholar 

  45. Caulier MT, Rose C, Roussel MT, et al. Pulsed high-dose dexamethasone in refractory chronic idiopathic thrombocytopenic purpura: a report on 10 cases. Br J Haematol 1995; 91: 477–9

    CAS  PubMed  Google Scholar 

  46. Figueroa M, Gehlsen J, Hammond D, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med 1993; 328: 1226–9

    CAS  PubMed  Google Scholar 

  47. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995; 85: 351–8

    CAS  PubMed  Google Scholar 

  48. Reid DM, Shulman NR. Pulse cyclophosphamide to treat idiopathic thrombocytopenic purpura. Blood 1995; 86: 415

    Google Scholar 

  49. Schultz KR, Strahlendorf C. Cyclosporin A therapy of immunemediated thrombocytopenia in children. Blood 1995; 85: 1406–8

    CAS  PubMed  Google Scholar 

  50. Godeau B, Oksenhendler E, Bierling P. Dapsone for autoimmune thrombocytopenic purpura. Am J Hematol 1993; 44: 70–2

    CAS  PubMed  Google Scholar 

  51. Kumakura S, Ishikura H, Tsumura H, et al. A favorable effect of long-term α-interferon therapy in refractory idiopathic thrombocytopenic purpura. Br J Haematol 1993; 85: 805–7

    CAS  PubMed  Google Scholar 

  52. Strother SV, Zuckerman KS, LoBuglio AR. Colchicine therapy for refractory idiopathic thrombocytopenic purpura. Arch Intern Med 1984; 144: 2198–200

    CAS  PubMed  Google Scholar 

  53. Belak M, Widder RA, Brunner R, et al. Immunoadsorption with protein A sepharose or silica. Lancet 1994; 343: 792–3

    CAS  PubMed  Google Scholar 

  54. Ericson SG, Coleman KD, Wardwell K, et al. Monoclonal antibody 197 (anti-FcγRI) in a patient with immune thrombocytopenic purpura (ITP) results in down-modulation of FcγRI on circulating monocytes. Br J Haematol 1996; 92: 718–24

    CAS  PubMed  Google Scholar 

  55. Carr JM, Kruskall MS, Kaye JA, et al. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 1986; 80: 1051–4

    CAS  PubMed  Google Scholar 

  56. Baumann MA, Menitove JE, Aster RH, et al. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med 1986; 104: 808–9

    CAS  PubMed  Google Scholar 

  57. Bussel JB, Pham LC. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang 1987; 52: 206–11

    CAS  PubMed  Google Scholar 

  58. Sullivan CA, Martin JN. Management of the obstetric patient with thrombocytopenia. Clin Obstet Gynecol 1995; 38: 521–34

    CAS  PubMed  Google Scholar 

  59. Yamada H, Fujimoto S. Perinatal management of idiopathic thrombocytopenic purpura in pregnancy: risk factors for passive immune thrombocytopenia. Ann Hematol 1994; 68: 39–42

    CAS  PubMed  Google Scholar 

  60. McCrae KR, Samuels P, Schreiber AD. Pregnancy-associated thrombocytopenia: pathogenesis and management. Blood 1992; 80: 2697–714

    CAS  PubMed  Google Scholar 

  61. Sharon R, Tatarsky I. Low fetal morbidity in pregnancy associated with acute and chronic idiopathic thrombocytopenic purpura. Am J Hematol 1994; 46: 87–90

    CAS  PubMed  Google Scholar 

  62. Cook RL, Miller RC, Katz VL, et al. Immune thrombocytopenic purpura in pregnancy: a reappraisal of management. Obstet Gynecol 1991; 78: 578–83

    CAS  PubMed  Google Scholar 

  63. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relationship to maternal thrombocytopenia. N Engl J Med 1993; 329: 1463–6

    CAS  PubMed  Google Scholar 

  64. Christiaens GCML, Helmerhost FM. Validity of intrapartum diagnosis of fetal thrombocytopenia. Am J Obstet Gynecol 1987; 157: 864–5

    CAS  PubMed  Google Scholar 

  65. Karpatkin M, Porges RF, Karpatkin S. Platelet counts in infants of women with autoimmune thrombocytopenia: effect of steroid administration to the mother. N Engl J Med 1981; 305: 936–9

    CAS  PubMed  Google Scholar 

  66. Kaplan C, Daffos F, Forestier F, et al. Fetal platelet counts in thrombocytopenic pregnancy. Lancet 1990; 336: 979–82

    CAS  PubMed  Google Scholar 

  67. Christiaens GCML, Nieuwenhuis HK, VonDemBorne AEGK, et al. Idiopathic thrombocytopenic purpura in pregnancy: a randomized trial on the effect of antenatal low dose corticosteroids on neonatal platelet count. Br J Obstet Gynaecol 1990; 97: 893–8

    CAS  PubMed  Google Scholar 

  68. Blanchette VS, Kirby MA, Turner C. Role of intravenous immunoglobulin G in autoimmune hematologic disorders. Semin Hematol 1992; 29 Suppl. 2: 72–82

    CAS  PubMed  Google Scholar 

  69. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45: 139–59

    Google Scholar 

  70. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura: report of 25 cases and review of the literature. Medicine 1981; 60: 413–28

    CAS  PubMed  Google Scholar 

  71. Rock GA, Shumak KH, Buskard NA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393–7

    CAS  PubMed  Google Scholar 

  72. Bell WR, Braine HG, Ness PM, et al. Improved survival in thrombotic thrombocytopenic purpura — hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med 1991; 325: 398–403

    CAS  PubMed  Google Scholar 

  73. Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 1456–61

    CAS  PubMed  Google Scholar 

  74. Lau DH, Wun T. Early manifestation of thrombotic thrombocytopenic purpura. Am J Med 1993; 95: 544–5

    CAS  PubMed  Google Scholar 

  75. Hayward CPM, Sutton DMC, Carter WH, et al. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura — hemolytic uremic syndrome. Arch Intern Med 1994; 154: 982–7

    CAS  PubMed  Google Scholar 

  76. Novitzky N, Jacobs P, Rosenstrauch W. The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange?. Br J Haematol 1994; 87: 317–20

    CAS  PubMed  Google Scholar 

  77. Obrador GT, Zeigler ZR, Shadduck RK, et al. Effectiveness of cryosupernatant therapy in refractory and chronic relapsing thrombotic thrombocytopenic purpura. Am J Hematol 1993; 42: 217–20

    CAS  PubMed  Google Scholar 

  78. Byrnes JJ, Moake JL, Klug P, et al. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Med 1990; 34: 169–74

    CAS  Google Scholar 

  79. Moake JL, Chintagumpala M, Turner N, et al. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994; 84: 490–7

    CAS  PubMed  Google Scholar 

  80. Levin M, Grunwald HW. Use of vincristine in refractory thrombotic thrombocytopenic purpura. Acta Haematol 1991; 85: 37–40

    CAS  PubMed  Google Scholar 

  81. Bobbio-Pallavicini E, Porta C, Centurioni R, et al. Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura. Eur J Haematol 1994; 52: 222–6

    CAS  PubMed  Google Scholar 

  82. Durand JM, Lefevre P, Kaplanski G, et al. Vincristine for thrombotic thrombocytopenic purpura. Lancet 1992; 340: 977–8

    CAS  PubMed  Google Scholar 

  83. O’Connor NTJ, Bruce-Jones P, Hill LF. Vincristine therapy for thrombotic thrombocytopenic purpura. Am J Med 1992; 39: 234–6

    Google Scholar 

  84. O’Connor NTJ, O’Shea MJ, Hill LF. Vincristine for thrombotic thrombocytopenic purpura. Lancet 1992; 340: 490

    PubMed  Google Scholar 

  85. Patton JF, Manning KR, Case D, et al. Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura. Am J Hematol 1994; 47: 94–9

    CAS  PubMed  Google Scholar 

  86. Pereira A, Mazzara R, Monteagudo J, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting response to plasma exchange. Ann Hematol 1995; 70: 319–23

    CAS  PubMed  Google Scholar 

  87. Revell PR, Slater NGP. Antiplatelet therapy in thrombotic thrombocytopenic purpura. Lancet 1992; 340: 851–2

    CAS  PubMed  Google Scholar 

  88. del Zoppo GJ. Antiplatelet therapy in thrombotic thrombocytopenic purpura. Semin Hematol 1987; 24: 130–9

    PubMed  Google Scholar 

  89. Rosove MH, Winston GH, Goldfinger D. Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura. Ann Intern Med 1982; 96: 27–33

    CAS  PubMed  Google Scholar 

  90. Gordon LI, Kwaan HC, Rossi EC. Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy. Semin Hematol 1987; 24: 194–201

    CAS  PubMed  Google Scholar 

  91. Veltman GAM, Brand A, Leeksma OC, et al. The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura. Ann Hematol 1995; 70: 231–6

    CAS  PubMed  Google Scholar 

  92. Onundarson PT, Rowe JM, Heal JM, et al. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. Arch Intern Med 1992; 152: 791–6

    CAS  PubMed  Google Scholar 

  93. Finn NG, Wang JC, Hong KJ. High-dose intravenous γ-immunoglobulin infusion in the treatment of thrombotic thrombocytopenic purpura. Arch Intern Med 1987; 147: 2165–7

    CAS  PubMed  Google Scholar 

  94. Heyman MR, Sweet T. Thrombotic thrombocytopenic purpura treated with high-dose intravenous gamma globulin. South Med J 1990; 83: 1471–4

    CAS  PubMed  Google Scholar 

  95. Durand JM, Lefevre P, Kaplinski G, et al. Ineffectiveness of high-dose intravenous gammaglobulin infusion in thrombotic thrombocytopenic purpura. Am J Hematol 1993; 42: 234

    CAS  PubMed  Google Scholar 

  96. Durand JM, Lefevre P, Kaplanski G, et al. Deleterious effects of intravenous immunoglobulin in a patient with thrombotic thrombocytopenic purpura. Am J Hematol 1993; 44: 214–5

    CAS  PubMed  Google Scholar 

  97. Kierdorf H, Maurin N, Heinz B. Cyclosporine for thrombotic thrombocytopenic purpura. Ann Intern Med 1993; 118: 987–8

    CAS  PubMed  Google Scholar 

  98. Bachman WR, Brennan JK. Refractory thrombotic thrombocytopenic purpura treated with cyclosporine. Am J Hematol 1996; 51: 93–4

    CAS  PubMed  Google Scholar 

  99. Bird JM, Cummins D, Machin SJ. Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura. Lancet 1990; 336: 565–6

    CAS  PubMed  Google Scholar 

  100. Drew MJ. Resolution of refractory, classic thrombotic thrombocytopenic purpura after staphylococcal protein A immunoadsorption. Transfusion 1994; 34: 536–8

    CAS  PubMed  Google Scholar 

  101. Bobbio-Pallavicini E, Porta C, Tacconi F, et al. Intravenous prostacyclin infusion in thrombotic thrombocytopenic purpura: four case reports and review of the literature. Haematologica 1994; 79: 429–37

    CAS  PubMed  Google Scholar 

  102. Rock G, Shumak K, Kelton J, et al. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Transfusion 1992; 32: 710–4

    CAS  PubMed  Google Scholar 

  103. Ben-Yehuda D, Rose M, Michaeli Y, et al. Permanent neurological complications in patients with thrombotic thrombocytopenic purpura. Am J Hematol 1988; 29: 74–8

    CAS  PubMed  Google Scholar 

  104. Shumak KH, Rock GA, Nair RC, et al. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Ann Intern Med 1995; 122: 569–72

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division Hematology-Oncology, New England Medical Center, 750 Washington Street, Boston, Massachusetts, 02111, USA

    Shmuel Gillis

Authors
  1. Shmuel Gillis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gillis, S. The Thrombocytopenic Purpuras. Drugs 51, 942–953 (1996). https://doi.org/10.2165/00003495-199651060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199651060-00003

Keywords

Search

Navigation